Drugs / XmAb27564
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06005792 | Oct 2022 → Mar 2024 | atopic eczema, psoriasis | Xencor, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04857866 | Apr 2021 → Nov 2022 | — | Xencor, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XmAb27564 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06005792 ↗ |
| Modality | Protein / enzyme biologic | “XmAb27564 is an engineered IL-2 mutein” NCT04857866 ↗ |
| Route | Subcutaneous | “subcutaneously administered XmAb27564” NCT04857866 ↗ |